A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 728-735

  Stopeck, Alison T ^a   Unger, Joseph M ^b   Rimsza, Lisa M ^a   Bellamy, William T ^c   Iannone, Maria ^a   Persky, Daniel ^a   Leblanc, Michael ^b   Fisher, Richard ^d   Miller, Thomas ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Clinical trial; Non Hodgkin lymphoma; VEGF

Indexed keywords

BEVACIZUMAB; DIPHENHYDRAMINE; PARACETAMOL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BLEEDING; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETHARGY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERFORATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SALVAGE THERAPY; SOUTHWESTERN UNITED STATES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 67650866822     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902856808     Document Type: Article

References (34)

1. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
2. Benjamin LE, Keshet E. Conditioning switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94: 8761-8766.
3. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999;106:504-509.
4. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:167-172.
5. Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;68:91-100.
6. Salven P, Orpana A, Teerenhovi L, Joensuu H, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors, VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: A single-institution study of 200 patients. Blood 2000;96:3712-3718.
7. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007;170:1362-1369.
8. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
9. Kim KJ, Li B, Winer J, Houck K, Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;71:53-64.
10. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ. Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
11. Cobleigh MA, Langmuir Vk, Sledge GW, Miller KD. Haney L. Novotny WF. et al. Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;5(Suppl. 16):117-124.
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, et al. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000;92:1329-1336.
16. Stopeck, AT, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002;8:2798-2805.
17. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13: 2643-2650.
18. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4344.
19. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoman. J Clin Oncol 2006;24:16-24.
20. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma:mOdulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
21. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
22. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study. J ClinOncol 2008;26:399-405.
23. Mancuso P, Colleoni M Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
24. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008;88:38-47.
25. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker, and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998-1005.
26. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:2089-2093.
27. Breen EC. VEGF in biological control. J Cell Biochem 2007;102:1358-1367.
28. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-2902.
29. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celeboxib and metronomic 'lowdose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non- Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-5198.
30. Bertolini F. Chemotherapy and the tumor microenvironment: The contribution of circulating endothelial cells. Cancer Metastasis Rev 2008;27:95-101.
31. Khan SS, Solomon MA, McCoy JP Jr., et al. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005;64:1-8.
32. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671-680.
33. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
34. De Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003;83:271-285.